2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2729

Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Abstract Number: 2730

Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Abstract Number: 2731

Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Abstract Number: 2732

The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Abstract Number: 2733

Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus
Abstract Number: 2734

Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Abstract Number: 2735

Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Abstract Number: 2736

Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Abstract Number: 2737

HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Abstract Number: 2738

Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis
Abstract Number: 2739

Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
Abstract Number: 2740

Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex
Abstract Number: 2741

Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Abstract Number: 2742

Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Abstract Number: 2743

Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].